Roche presents exploratory data from the Phase III IMvigor010 study in early bladder cancer at the ESMO Immuno-Oncology Virtual Congress 2020

Basel, 10 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today presented an exploratory analysis from the Phase III IMvigor010 study evaluating Tecentriq ® (atezolizumab), compared with observation, as an adjuvant (after surgery) monotherapy treatment for people with muscle-invasive urothelial cancer (MIUC) at the European Society for Medical Oncology Immuno-Oncology (ESMO IO) Virtual Congress, 9–12 December 2020.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news